Navigation Links
Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
Date:12/14/2010

PARSIPPANY, N.J., Dec. 14, 2010 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, announced today that the New Drug Application (NDA) for EXPAREL™, a long-acting bupivacaine for postsurgical pain management, has been accepted for filing by the U.S. Food and Drug Administration (FDA). Pacira submitted the EXPAREL NDA in September 2010 for the initial indication of postsurgical analgesia by local administration. The FDA also notified Pacira that its Prescription Drug User Fee Act (PDUFA) target date (the date the FDA expects to complete its review of the EXPAREL NDA) is July 28, 2011.  

About PaciraPacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, commercialization and manufacture of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. The company's most advanced product candidate, EXPAREL, a bupivacaine-based product, has completed Phase 3 clinical development for postoperative analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at www.pacira.com.ContactJames S. Scibetta, CFO, Pacira Pharmaceuticals, Inc.973-254-3560
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
4. ISTA Pharmaceuticals Initiates Phase 2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
5. Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders
6. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
7. Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders
8. Syndax Pharmaceuticals Entinostat in Combination Shows Activity in Breast Cancer
9. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
10. Access Pharmaceuticals Reports Significant Third Party Payer Reimbursement Progress for MuGard
11. Syndax Pharmaceuticals Entinostat Plus Erlotinib Improves Survival in Select NSCLC Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... July 5, 2017 Pace Analytical, a company of over 2,000 employees ... they have acquired ESC Lab Sciences, further solidifying their position as the top ... . ... President and CEO of Pace Analytical ... Sciences out of Mt Juliet, TN , enhances Pace Analytical,s ...
(Date:6/30/2017)... June 30, 2017 In vitro diagnostics market ... of May, at least ten diagnostic companies have successfully ... public offerings and a loan facility.  The size of ... $80 million.  Kalorama Information provides a monthly IVD ... Diagnostics Knowledge Center. ...
(Date:6/27/2017)... June 27, 2017  Therapix Biosciences Ltd. (Nasdaq: ... specializing in the development of cannabinoid-based drugs, today announced ... Opening Bell in New York, NY ... its initial public offering (IPO) of American Depository Shares ... 2017. Dr. Elran Haber, Ph.D., Chief Executive ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 21, 2017 , ... West Dermatology is pleased to announce the newest addition ... 2017, Ms. Vu will join West Dermatology’s large network of medical and cosmetic dermatology ... cancer , and more. She graduated from the University of Florida College of Medicine ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is a set ... the FCPX timeline. This effect isolates horizontal and vertical lines of pixels and sorts ... a rotating or flipping animation and can be changed using a drop-down menu. Create ...
(Date:7/20/2017)... ... July 20, 2017 , ... Coats Rose, P.C. , ... announce their expansion to the Midwest with the establishment of the firm’s new ... Bell, and of counsels, John Peck and Robert Bruns, will establish and anchor ...
(Date:7/20/2017)... ... July 20, 2017 , ... Doctors on Liens, the leading network of ... Chiropractic , directed by Dr. Russell Horine, DC to their exclusive list of medical ... Dr. Russell Horine serving as the clinic director and his son Dr. Lee Horine ...
(Date:7/20/2017)... ... 2017 , ... The Dermatology Clinic announced today the addition of Dr. Scott ... from LSU, graduating summa cum laude. He attended Emory University School of Medicine in ... Louis, Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs surgery fellowship ...
Breaking Medicine News(10 mins):